Hem

Press release from Companies

Publicerat: 2021-09-24 13:00:20

Genetic Analysis AS: Genetic Analysis AS (GEAN): Disclosure of Large Shareholding

OSLO, NORWAY – 24 September 2021: Reference is made to the press release on 15 September 2021 from Genetic Analysis AS ("the Company", XSAT ticker: GEAN) regarding a public placement of 7,700,00 new shares in the Company at a subscription price of NOK 7.80 per share prior to the listing on the Spotlight Stock Market on 1 October 2021.

Bio-Rad Laboratories Inc ("Bio-Rad") has been allocated 532,050 new shares and 691,665 new warrants in Genetic Analysis AS. After issue and registration of the new shares, Bio-Rad will hold 5,297,205 shares in Genetic Analysis AS, equalling 21.26% of the shares and votes in the Company. In addition, Bio-Rad holds 691,665 warrants.

For more information, please contact:
Eilert Aamodt, CFO
E-mail: ea@genetic-analysis.com

About Genetic Analysis 

Genetic Analysis AS (GA) is a science-based diagnostic company and pioneer in the human microbiome field with more than 10 years of expertise in research and product development.  The unique GA-map® platform is based on a pre-targeted multiplex approach specialized for simultaneous analysis of a large number of bacteria in one reaction. The test results are generated by utilizing the clinically validated cutting edge GA-map® software algorithm. This enables immediate results without the need of further bioinformatics work. GA’s vision is to become the leading company for standardized gut microbiota testing worldwide, and GA is committed to help unlocking and restoring the human microbiome through its state-of-the-art technology. GA holds 22 highly qualified employees with relevant scientific backgrounds and with competence in bioinformatics, molecular biology, and bioengineering. www.genetic-analysis.com

Läs mer hos Cision
Läs mer om Genetic Analysis AS

Prenumeration